Your session is about to expire
← Back to Search
FOLFIRINOX + Digoxin for Pancreatic Cancer
Study Summary
This trial is testing a new combination of drugs for pancreatic cancer that may be more effective and have fewer side effects than current treatment.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I cannot have a laparoscopy due to many past abdominal surgeries.I understand my disease is cancerous and I have given written consent.I cannot take digoxin due to health reasons.Your blood levels of potassium, magnesium, and calcium are within the normal range.I have not had chemotherapy for pancreatic cancer.I do not have any serious ongoing illnesses like heart failure or uncontrolled infections.My pancreatic cancer is confirmed and can be surgically removed without spread.Your white blood cell count is at least 1000/μL and your platelet count is at least 100,000/μL.Your total bilirubin levels should be less than 1.5 mg/dL, unless you have Gilbert disease with indirect bilirubin less than 1.0 mg/dL, or if you need treatment for bile duct blockage.I have a known immune system disorder.I had chemotherapy for a cancer other than pancreatic over 5 years ago and am now cancer-free.I have HIV or active hepatitis B or C.I am fully active or can carry out light work.You have an ongoing autoimmune disease.I am 19 years old or older.I have no cancer history in the last 5 years, except for certain skin cancers or noninvasive cancers that were treated.My kidney function is normal, with creatinine ≤ 2.0 mg/dL.You must have a disease that can be seen on a medical scan.
- Group 1: Treatment
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
In what types of cases is 5Fluorouracil typically administered?
"5-Fluorouracil is a common treatment for small cell lung cancer (sclc) and has also been used to treat joint pain, rectal carcinoma, and colorectal carcinoma."
How many participants have been recruited for this clinical experiment?
"Affirmative. Trials data publicly accessible on clinicaltrials.gov suggest that this experiment is still actively seeking volunteers, with the initial posting occuring on February 12th 2021 and the most recent update occurring March 31st 2022. The study requires 20 participants to be recruited from a single site."
Are applications currently being accepted for the clinical trial?
"Affirmative. According to the clinicaltrials.gov record, this research project is actively recruiting participants; it was opened on February 12th 2021 and its last modification occurred on March 31st 2022. It requires 20 people from 1 site for completion."
Could you elaborate on which other investigations have utilized 5Fluorouracil?
"Presently, 666 studies are being conducted to further understand 5Fluorouracil. Of those trials 207 have progressed to Phase 3 and these are predominantly based in Guangzhou, Guangdong. Additionally, the research is also taking place at 27690 other locations around the world."
Has the Federal Drug Administration given sanction to 5Fluorouracil?
"Our assessment of 5Fluorouracil's safety is a 2, as there are some reports backing its security but none demonstrating the drug's efficacy."
Share this study with friends
Copy Link
Messenger